Key facts
- Cubed Biotech’s last known valuation is $25.4M.
- It has raised $11.8M across 1 recorded rounds; the latest was Seed Round ($500K) in Dec 2024.
- Notable investors include VentureCrowd.
- Cubed Biotech has filed 1 Form D with the SEC, most recently Jan 2025 ($500K sold to 3 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cubed Biotech
Funding rounds
1 roundsAbout Cubed Biotech
Operator of a biotech firm intended to manufacture natural multi-psychedelic medicines. The company's platform cultivates, extracts, purify & synthesize natural entheogens (i.e., psilocybin from mushrooms, mescaline from cacti, and ayahuasca's DMT and monoamine oxidase inhibitors) such as mushrooms, cacti, and ayahuasca for mental health and addiction issues, it is federally licensed to develop, manufacture, and commercialize psychedelic medicine to unnerve the current treatments of mental illness & addiction, enabling patients suffering from depression and anxiety to get relief from all of their mental health disorders.
- Sector
- Healthcare
- HQ
- Dollard-des Ormeaux, Canada
- Founded
- 2020
- Employees
- 8
- Website
- cubed3biotech.com/
- Ownership
- Privately Held (backing)
Cubed Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cubed Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cubed Biotech in its N-PORT filings yet. We sweep new filings monthly.